Literature DB >> 23703401

Predictive factors for gastroduodenal toxicity based on endoscopy following radiotherapy in patients with hepatocellular carcinoma.

H Yoon1, D Oh, H C Park, S W Kang, Y Han, D H Lim, S W Paik.   

Abstract

PURPOSE: The aim of this work was to determine predictive factors for gastroduodenal (GD) toxicity in hepatocellular carcinoma (HCC) patients who were treated with radiotherapy (RT). PATIENTS AND METHODS: A total of 90 HCC patients who underwent esophagogastroduodenoscopy (EGD) before and after RT were enrolled. RT was delivered as 30-50 Gy (median 37.5 Gy) in 2-5 Gy (median 3.5 Gy) per fraction. All endoscopic findings were reviewed and GD toxicities related to RT were graded by the Common Toxicity Criteria for Adverse Events, version 3.0. The predictive factors for the ≥ grade 2 GD toxicity were investigated.
RESULTS: Endoscopic findings showed erosive gastritis in 14 patients (16 %), gastric ulcers in 8 patients (9 %), erosive duodenitis in 15 patients (17 %), and duodenal ulcers in 14 patients (16 %). Grade 2 toxicity developed in 19 patients (21 %) and grade 3 toxicity developed in 8 patients (9 %). V25 for stomach and V35 for duodenum (volume receiving a RT dose of more than x Gy) were the most predictive factors for ≥ grade 2 toxicity. The gastric toxicity rate at 6 months was 2.9 % for V25 ≤ 6.3 % and 57.1 % for V25 > 6.3 %. The duodenal toxicity rate at 6 months was 9.4 % for V35 ≤ 5.4 % and 45.9 % for V35 > 5.4 %. By multivariate analysis including the clinical factors, V25 for stomach and V35 for duodenum were the significant factors.
CONCLUSION: EGD revealed that GD toxicity is common following RT for HCC. V25 for the stomach and V35 for the duodenum were the significant factors to predict ≥ grade 2 GD toxicity.

Entities:  

Mesh:

Year:  2013        PMID: 23703401     DOI: 10.1007/s00066-013-0343-0

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  22 in total

Review 1.  Does portal hypertension contribute to the pathogenesis of gastric ulcer associated with liver cirrhosis?

Authors:  S Kitano; B Dolgor
Journal:  J Gastroenterol       Date:  2000       Impact factor: 7.527

2.  Radiotherapy for hepatocellular carcinoma.

Authors:  K Tokuuye; M Sumi; Y Kagami; S Murayama; M Kawashima; H Ikeda; H Ueno; T Okusaka; S Okada
Journal:  Strahlenther Onkol       Date:  2000-09       Impact factor: 3.621

3.  Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes.

Authors:  Sang Min Yoon; Young-Suk Lim; Hyung Jin Won; Jong Hoon Kim; Kang Mo Kim; Han Chu Lee; Young-Hwa Chung; Yung Sang Lee; Sung Gyu Lee; Jin-Hong Park; Dong Jin Suh
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-05-27       Impact factor: 7.038

4.  Prevalence of gastric ulcer in cirrhotic patients and its relation to portal hypertension.

Authors:  L S Chen; H C Lin; S J Hwang; F Y Lee; M C Hou; S D Lee
Journal:  J Gastroenterol Hepatol       Date:  1996-01       Impact factor: 4.029

5.  Dose-volume analysis of predictors for gastrointestinal toxicity after concurrent full-dose gemcitabine and radiotherapy for locally advanced pancreatic adenocarcinoma.

Authors:  Jiayi Huang; John M Robertson; Hong Ye; Jeffrey Margolis; Laura Nadeau; Di Yan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-11-16       Impact factor: 7.038

6.  The role of propranolol in congestive gastropathy of portal hypertension.

Authors:  S W Hosking; H J Kennedy; I Seddon; D R Triger
Journal:  Hepatology       Date:  1987 May-Jun       Impact factor: 17.425

7.  The treatment responses in cases of radiation therapy to portal vein thrombosis in advanced hepatocellular carcinoma.

Authors:  Yu-Jie Huang; Hsuan-Chih Hsu; Chang-Yu Wang; Chong-Jong Wang; Hui-Chun Chen; Eng-Yen Huang; Fu-Min Fang; Sheng-Nan Lu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-08-28       Impact factor: 7.038

8.  Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome.

Authors:  Michael T Milano; Steven J Chmura; Michael C Garofalo; Carla Rash; John C Roeske; Phillip P Connell; Oh-Hoon Kwon; Ashesh B Jani; Ruth Heimann
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-06-01       Impact factor: 7.038

9.  Predictive factors of gastroduodenal toxicity in cirrhotic patients after three-dimensional conformal radiotherapy for hepatocellular carcinoma.

Authors:  Haeyoung Kim; Do Hoon Lim; Seung Woon Paik; Byung Chul Yoo; Kwang Gheol Koh; Joon Hyoek Lee; Moon Seok Choi; Won Park; Hee Chul Park; Seung Jae Huh; Doo Ho Choi; Yong Chan Ahn
Journal:  Radiother Oncol       Date:  2009-06-11       Impact factor: 6.280

10.  Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.

Authors:  Baosheng Li; Jinming Yu; Liying Wang; Chengjun Li; Tao Zhou; Limin Zhai; Ligang Xing
Journal:  Am J Clin Oncol       Date:  2003-08       Impact factor: 2.339

View more
  14 in total

Review 1.  Inclusion of dosimetric data as covariates in toxicity-related radiogenomic studies : A systematic review.

Authors:  Noorazrul Yahya; Xin-Jane Chua; Hanani A Manan; Fuad Ismail
Journal:  Strahlenther Onkol       Date:  2018-05-17       Impact factor: 3.621

2.  Simultaneous integrated boost-intensity modulated radiation therapy for inoperable hepatocellular carcinoma.

Authors:  Tae Hyun Kim; Joong-Won Park; Yeon-Joo Kim; Bo Hyun Kim; Sang Myung Woo; Sung Ho Moon; Sang Soo Kim; Woo Jin Lee; Dae Yong Kim; Chang-Min Kim
Journal:  Strahlenther Onkol       Date:  2014-03-18       Impact factor: 3.621

3.  Feasibility of normal tissue dose reduction in radiotherapy using low strength magnetic field.

Authors:  Nuri Hyun Jung; Youngseob Shin; In-Hye Jung; Jungwon Kwak
Journal:  Radiat Oncol J       Date:  2015-09-30

4.  Consensus for Radiotherapy in Hepatocellular Carcinoma from The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials.

Authors:  Hee Chul Park; Jeong Il Yu; Jason Chia-Hsien Cheng; Zhao Chong Zeng; Ji Hong Hong; Michael Lian Chek Wang; Mi Sook Kim; Kwan Hwa Chi; Po-Ching Liang; Rheun-Chuan Lee; Wan-Yee Lau; Kwang Hyub Han; Pierce Kah-Hoe Chow; Jinsil Seong
Journal:  Liver Cancer       Date:  2016-05-03       Impact factor: 11.740

Review 5.  Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis.

Authors:  Jeong Il Yu; Hee Chul Park
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

6.  Gastric injury from (90)Y to left hepatic lobe tumors adjacent to the stomach: fact or fiction?

Authors:  Vanessa L Gates; Ryan Hickey; Karen Marshall; Melissa Williams; Krystina Salzig; Robert J Lewandowski; Riad Salem
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-21       Impact factor: 9.236

7.  Radiotherapy for patients with isolated local recurrence of primary resected pancreatic cancer. Prolonged disease-free interval associated with favorable prognosis.

Authors:  Akira Nakamura; Satoshi Itasaka; Kyoichi Takaori; Yoshiya Kawaguchi; Keiko Shibuya; Michio Yoshimura; Yukinori Matsuo; Takashi Mizowaki; Shinji Uemoto; Masahiro Hiraoka
Journal:  Strahlenther Onkol       Date:  2014-03-06       Impact factor: 3.621

8.  Do Biliary Complications after Hypofractionated Radiation Therapy in Hepatocellular Carcinoma Matter?

Authors:  Jeong Il Yu; Hee Chul Park; Do Hoon Lim; Seung Woon Paik
Journal:  Cancer Res Treat       Date:  2015-07-17       Impact factor: 4.679

9.  Clinical safety and efficacy of salvage reirradiation for upper abdominal malignancies.

Authors:  Jason Joon Bock Lee; Seo Hee Choi; Jung Ho Im; Jinsil Seong
Journal:  Strahlenther Onkol       Date:  2019-01-28       Impact factor: 3.621

10.  Predictive dosimetric parameters for gastrointestinal toxicity with hypofractioned radiotherapy in pancreatic adenocarcinoma.

Authors:  Xian Liu; Gang Ren; Liqin Li; Tingyi Xia
Journal:  Onco Targets Ther       Date:  2016-04-26       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.